ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE)

ClinicalTrials.gov ID: NCT04264442

Public ClinicalTrials.gov record NCT04264442. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 11:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 48-Week, Parallel-Group Study of the Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE)

Study identification

NCT ID
NCT04264442
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Fulcrum Therapeutics
Industry
Enrollment
76 participants

Conditions and interventions

Interventions

  • Losmapimod Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 12, 2020
Primary completion
Nov 6, 2024
Completion
Nov 6, 2024
Last update posted
Sep 29, 2025

2020 – 2024

United States locations

U.S. sites
12
U.S. states
11
U.S. cities
12
Facility City State ZIP Site status
University of California Irvine Irvine California 92868
University of California Los Angeles (UCLA) Los Angeles California 90095
University of Florida Gainesville Florida 32610
University of Kansas Medical Center Kansas City Kansas 66160
Kennedy Krieger Institute Baltimore Maryland 21205
University of Massachusetts Memorial Medical Center Worcester Massachusetts 01655
Washington University School of Medicine St Louis Missouri 63110
University of Rochester Medical Center Rochester New York 14642
Ohio State University Columbus Ohio 43221
University of Utah Salt Lake City Utah 84132
Virginia Commonwealth University Richmond Virginia 23298
University of Washinton Medical Center Seattle Washington 98195

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04264442, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 29, 2025 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04264442 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →